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Abstract 
Structural studies on the non-translational 
function of human asparaginyl-tRNA synthetase 
as a novel chemokine targeting CCR3 
Joon Sung Park 
Division of Pharmaceutical Bioscience 
College of Pharmacy 
The Graduate School 
Seoul National University 
 
Asparaginyl-tRNA synthetase (NRS) is not only essential in 
protein translation but also associated with autoimmune diseases. 
Particularly, patients with antibodies that recognize NRS often 
develop interstitial lung disease (ILD). However, the underlying 
mechanism of how NRS is recognized by immune cells and provokes 
inflammatory responses is not well-understood. Here, I found that 
ii 
the crystal structure of the unique N-terminal extension domain of 
human NRS (named as UNE-N, where -N denotes NRS) resembles 
that of the chemotactic N-terminal domain of NRS from a filarial 
nematode, Brugia malayi, which recruits and activates specific 
immune cells by interacting with CXC chemokine receptor 1 and 2. 
UNE-N induced migration of C-C chemokine receptor 3 (CCR3)-
expressing cells. The chemokine activity of UNE-N was 
significantly reduced by suppressing CCR3 expression with CCR3-
targeting siRNA, and the loop3 region of UNE-N was shown to 
interact mainly with the extracellular domains of CCR3 in nuclear 
magnetic resonance perturbation experiments. Based on these 
results, evolutionarily acquired UNE-N elicits chemokine activities 
that would promote NRS-CCR3-mediated proinflammatory 
signaling in ILD. 
 
Keywords: Human asparaginyl-tRNA synthetase (NRS), chemokine, 
CC chemokine receptor 3 (CCR3), X-ray crystallography, 
antisynthetase syndrome 
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1. Introduction 
1.1 Aminoacyl-tRNA synthetase 
Aminoacyl-tRNA synthetases (ARSs) play a fundamental role in 
protein synthesis by charging tRNAs with matching amino acids. 
Their reaction is composed of two steps; the first step is formation 
of aminoacyl-AMP by consuming ATP to AMP and the second step 
is conjugation of the aminoacyl moiety to tRNA (Fig. 1). ARSs could 
be classified into two classes; class 1 and class 2 based on their 






Figure 1. Two steps of tRNA aminoacylation catalyzed by ARSs. 
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Table 1. Classification of ARSs
3
. 
Class Subclass ARS (Form) Organism PDB ID 
1 
a 
Isoleucyl-tRNA synthetase (α) Thermus thermophilus 1ILE 
Methionyl-tRNA synthetase (α2) Thermus thermophilus 1A8H 
Leucyl-tRNA synthetase (α) Thermus thermophilus 1H3N 
Valyl-tRNA synthetase (α) Thermus thermophilus 1GAX 
b 
Cysteinyl-tRNA synthetase (α) Escherichia coli 1LI5 
Glutaminyl-tRNA synthetase (α) Saccharomyces cerevisiae 4H3S 
Glutamyl-tRNA synthetase (α) Thermus thermophilus 1J09 
c 
Tyrosyl-tRNA synthetase (α2) Thermus thermophilus 1H3F 
Tryptophanyl-tRNA synthetase (α2) Homo sapiens 2AKE 
d Arginyl-tRNA synthetase (α) Thermus thermophilus 1IQ0 
e Lysyl-tRNA synthetase Ⅰ (α) Pyrococcus horikoshii 1IRX 
2 
a 
Glycyl-tRNA synthetase (α2) Thermus thermophilus 1ATI 
Histidyl-tRNA synthetase (α2) Escherichia coli 1HTT 
Prolyl-tRNA synthetase (α2) Plasmodium falciparum 4TWA 
Seryl-tRNA synthetase (α2) Methanosarcina barkeri 2CJB 
Threonyl-tRNA synthetase (α2) Escherichia coli 1QF6 
b 
Asparaginyl-tRNA synthetase (α2) Brugia malayi 2XGT 
Aspartyl-tRNA synthetase(α2) Saccharomyces cerevisiae 1ASY 
Lysyl-tRNA synthetase Ⅱ (α2) Homo sapiens 4YCU 
c 
Alanyl-tRNA synthetase (α4) Archaeoglobus fulgidus 3WQY 
Glycyl-tRNA synthetase (α2β2) Homo sapiens 2ZT5 
Phenylalanyl-tRNA synthetase (α2β2) Thermus thermophilus 1B70 
Pyrolysyl-tRNA synthetase (α2) Methanosarcina mazei 2Q7H 
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Each class 1 ARS features a Rossman fold that comprises 
a parallel β-sheet in its nucleotide binding site. In addition, class 1 
ARSs share the mechanism of reaction that initially attaches an 
amino acid to 2′-OH of the target adenosine and sequentially 
transfers the amino acid to 3′-OH of the adenosine. Class 2 ARSs 
commonly have anti-parallel β-sheets in their nucleotide binding 
sites and directly attach amino acids to 3′-OH of their substrate 




Figure 2. Conserved structures of class 1 and class 2 ARSs. Structural alignment of 
catalytic domains of class 1 and class 2 ARSs shows shared Rossman folds and 
anti-parallel β-sheet structures, respectively. N- and C-termini of backbone 
brackets in class 1 ARSs and arginine tweezers in class 2 ARSs are colored in blue 
and red, respectively. (Source: adapted from "Alignment of the core domains of 




In addition to translational functions, higher eukaryotic 
ARSs are known to play roles in various physiological events such 
as vascular development, angiogenesis, cytokine signaling, 
tumorigenesis, inflammation, apoptosis, neural development, and 
immunological response via their evolutionarily acquired domains 
and alternative splicing variants of catalytic nulls5-8 (Fig. 3 and Fig. 
4). Higher eukaryotes have also developed a multi-aminoacyl-
tRNA synthetase complex (MSC) that serves as a reservoir and 
regulatory machinery of translational or non-translational functions 




Figure 3. Non-translational functions of recombinant ARSs. Recombinant ARS 
variants were tested in cell-based assays, which showed that the ARS variants are 
involved in a variety of biological events. (From Lo, W. S. et al. Human tRNA 
synthetase catalytic nulls with diverse functions. Science 345, 328-332, 




Figure 4. Splice variants of mammalian ARSs. Catalytic domains are abrogated in 
most splice variants of ARSs but domains involved in non-translational function 
are predominantly retained. (From Lo, W. S. et al. Human tRNA synthetase 
catalytic nulls with diverse functions. Science 345, 328-332, 




Figure 5. Schematic representation of the organization of MSC. A human MSC is 
composed of nine different ARSs and three auxiliary proteins (AIMP1, 2, and 3) in 
mammals. EPRS, glutamyl-prolyl-tRNA synthetase; IRS, isoleucyl-tRNA 
synthetase; LRS, leucyl-tRNA synthetase; MRS, methionyl-tRNA synthetase; 
QRS, glutaminyl-tRNA synthetase; KRS, lysyl-tRNA synthetase; RRS, arginyl-
tRNA synthetase; DRS, aspartyl-tRNA synthetase; AIMP, aminoacyl-tRNA 
synthase complex-interacting multifunctional protein. (Reprinted from Rajendran, 
V. et al. Aminoacyl-tRNA synthetases: Structure, function, and drug discovery. Int 
J Biol Macromol 111, 400-414, doi:10.1016/j.ijbiomac.2017.12.157 (2018), with 
permission from Elsevier)  
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1.2. Class 2b ARS 
NRS, DRS, and KRS are classified as class 2b ARSs that share 
sequence motifs in their canonical domains (CD) which are 
composed of an anticodon-binding domain (ABD), a hinge region 
(HR), and a catalytic domain11 (Fig. 6). Class 2b ARSs feature 
homodimeric assembly and eukaryote-specific N-terminal 
extension domains which modulate the bindings of substrate tRNAs 
with their lysine-rich xSKxxLKKxxK helical motifs11-17. In humans, 
the unique N-terminal extension domain of NRS (named as UNE-N 
where -N denotes NRS) is about 100 amino acids, which is longer 





Figure 6. Crystal structure of DRS. Crystal structure of DRS is shown in cartoon 
representation (PDB ID: 4J15). DRS is one of class 2b ARSs and forms a 
homodimer. It has a modular structure with an N-terminal extension domain, an 






1.3. Chemokine activities of NRS 
NRSs from human and Brugia malayi were reported to have 
chemokine activities18,19. Human NRS could induce migration of 
immune cells such as immature dendritic cells and lymphocytes 
through CCR3-mediated signaling. B. malayi is an infectious 
nematode causing filariasis in humans and it secrets a large amount 
of Brugia malayi NRS (BmNRS) during infection. The secreted 
BmNRS participates in the development of pathological responses 
by its interleukin 8 (IL-8)-like activities which modulate the host 
immune system19-22 and stimulates endothelial cell proliferation, 
vasodilation, and angiogenesis23. BmNRS also induces the migration 
of immune cells that is mediated by CXC chemokine receptor 1 
(CXCR1) and 2 (CXCR2)19,22. Based on the structural similarity to 
IL-8 and stromal cell derived factor-1, the hairpin-helix structure 
in UNE-N of BmNRS was suggested as the effector motif for its 
receptor recognition16,22 (Fig. 7). 
13 
 
Figure 7. Solution structure of UNE-N of BmNRS. Structure of UNE-N of BmNRS 
(Met1–Glu74, PDB ID: 2KQR) is shown in cartoon representation. α-helices, β-
strands, and loops are colored in palegreen, salmon, and yellow, respectively. 
UNE-N of BmNRS contains a hairpin-helix motif, β2-β3-α2, which was 
suggested as the crucial motif to the chemokine activities. 
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1.4. Antisynthetase syndrome 
Autoantibodies against eight ARSs have been identified in 
antisynthetase syndrome associated with interstitial lung disease 
(ILD) and idiopathic inflammatory myopathies: anti-Jo-1 (HRS), 
anti-PL-7 (threonyl-tRNA synthetase), anti-PL-12 (alanyl-
tRNA synthetase), anti-OJ (IRS), anti-EJ (glycyl-tRNA 
synthetase), anti-KS (NRS), anti-Ha (tyrosyl-tRNA synthetase), 
and anti-Zo (phenylalanyl-tRNA synthetase)24-26 (Fig. 8). 
Autoantibody-targeted ARSs are released in specific immune 
conditions and some of them have been known to elicit chemotactic 
activities18,27,28. Anti-Jo-1, autoantibodies to HRS, is most 
frequently observed in antisynthetase syndrome, and HRS has been 
shown to induce migration of CD4+ (cluster of differentiation 4) and 
CD8+ (cluster of differentiation 8) lymphocytes, interleukin-2-
activated monocytes, and immature dendritic cells (iDCs) in a CC 
chemokine receptor (CCR) 5-dependent manner. Similarly, anti-
KS, autoantibodies to NRS, is often detected in patients with ILD26 





Figure 8. Distributions of clinical diagnoses in patients with anti-ARS antibodies. 
The patients with anti-KS showed the most dominant prevalence (77%) of ILD 
alone. DM, dermatomysitis; CADM, clinically amyopathic DM; PM, polymyositis; 
SLE, systemic lupus erythematosus; SSc, systemic sclerosis. (Source: adapted 
from Hamaguchi, Y. et al. Common and distinct clinical features in adult patients 
with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the 
syndrome. PLoS One 8, e60442, doi:10.1371/journal.pone.0060442 (2013) (CC BY 
4.0), https://doi.org/10.1371/journal.pone.0060442.g003)  
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1.5. Chemokine 
Chemokines are the cytokines with chemotactic activities and 
classified into C, CC, CXC, and CX3C chemokines based on the 
conserved motifs of cysteines that are participating in 
intramolecular disulfide bonds with other cysteines29. Typical 
structure of a chemokine contains an antiparallel β-sheet of three 
β-strands and a following C-terminal α-helix (β1-β2-β3-
α1), which forms the Greek key shape (Fig. 9). Chemokine 
receptors are also classified into XCR, CCR, CXCR, and CX3CR 
receptors depending on the types of chemokines they recognize. 
They are the members of G-protein coupled receptor family that 
have seven transmembrane helices and four extracellular domains. 
CCL5 and CCL11 are the representative CC chemokines targeting 
CCR3 which mediates chemotactic activities in the CCR3-




Figure 9. Typical structure of a chemokine. Solution structure of CCL11 is shown in 




So far, at least three reasonable manifestations of NRS-
autoimmune disease relationship have been accumulated; 1) 
autoantibodies to NRS have been observed in the patients with ILD, 
2) NRS can elicit CCR3-mediated signaling in specific immune 
conditions, and 3) UNE-N of BmNRS, which is homologous to 
UNE-N of human, is able to recruit particular chemokine receptors 
to provoke pathological effects. To decipher the connections 
between NRS, CCR3, and autoimmune diseases at a molecular level, 
I determined the crystal structures of UNE-N and CD of NRS and 
further examined molecular dynamics of UNE-N that was 
speculated as an effector domain to CCR3. Several conditions for 
NRS secretion and chemokine activities of full-length NRS, UNE-N, 
and CD were tested. For further information of the direct interaction 
between NRS and CCR3, pull-down assays were implemented and 
NMR chemical shift changes of UNE-N in the absence and 
presence of each extracellular domain (ED) of CCR3 were 
measured through NMR perturbation experiments. In conclusion, I 
suggest that the evolutionarily acquired UNE-N could be a 
fundamental determinant of immunological importance, thus a niche 
for unraveling a complicated NRS-related autoimmune problem. 
19 
2. Materials and Methods 
2.1. Cloning, protein expression, and purification 
NRS constructs for CD (residues 98–548) and UNE-N variants 
(residues 1–77, 4–77, and 1–111) were designed based on 
secondary structure prediction with the XtalPred server31 and 
structure of BmNRS16 (Fig. 10). 
Full-length NRS and CD (residues 98–548) were cloned 
into the pET-28a(+) plasmid (Novagen, Madison, WI, USA) 
between the Nde1 and Xho1 restriction sites. Each construct 
contained an N-terminal hexahistidine tag. NRS and CD were 
overexpressed in the C41(DE3) and Solu-BL21, Escherichia coli 
(E. coli) strains, respectively. The transformed cells were grown at 
37 ℃ to an OD600 of 0.5 in Luria-Bertani media containing 
kanamycin and protein expression was induced by 0.5 mM isopropyl 
β-D-1-thiogalactopyranoside. The cells were incubated for 
additional 8 h and then harvested by centrifugation at 6,000 ×g for 
10 min. The harvested cells were resuspended in buffer A (500 mM 
NaCl, 20 mM Tris-HCl, 35 mM imidazole, pH 7.5) with 1 mM 
phenylmethylsulfonyl fluoride and lysed by sonication. Lysed cells 
were centrifuged at 35,000 ×g for 1 h. The resulting supernatants 
were filtered with a 0.45-μm syringe filter device (Sartorius, 
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Gottingen, Germany) and loaded onto a 5-mL HiTrap chelating HP 
column (GE Healthcare) which had been pre-charged with Ni2+ and 
equilibrated with buffer A. After washing with buffer A, the retained 
proteins were eluted by addition of an increasing gradient of buffer 
B (500 mM NaCl, 20 mM Tris-HCl, 1 M imidazole, pH 7.5). The 
proteins were loaded onto a HiPrep desalting 26/10 column (GE 
Healthcare) and eluted with buffer C (50 mM NaCl, 20 mM Tris-
HCl, pH 7.5). The eluates were loaded onto a HiTrap 5-ml Q HP 
(GE Healthcare) column. The loaded column was washed with 
buffer C and the retained proteins were eluted with an increasing 
gradient of buffer D (1 M NaCl, 20 mM Tris-HCl, pH 7.5). The 
proteins were finally purified over a HiLoad 16/600 Superdex 200 
pg (GE Healthcare) column with appropriate buffers: buffer E (200 
mM NaCl, 10 mM Tris-HCl, pH 7.5) for crystallization and 
phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 








Figure 11. Purification of full-length NRS: Ni
2+
 affinity chromatography (A), anion 
exchange chromatography (B), and size exclusion chromatography (C). Purity of 




Figure 12. Purification of CD: Ni
2+
 affinity chromatography (A), anion exchange 
chromatography (B), and size exclusion chromatography (C). Purity of the protein 
fractions was checked by SDS-PAGE analysis after each purification step.  
24 
The UNE-N constructs were cloned into the pET-28a(+) 
plasmid between the Nde1 and Xho1 restriction sites. Each 
construct contained a hexahistidine tag, maltose binding protein 
(MBP), and tobacco etch virus (TEV) protease cleavage site at the 
N-terminus. Recombinant proteins were overexpressed in Rosetta 
2(DE3), an E. coli strain. E. coli growth, protein expression, and 
purification up to hexahistidine tag affinity chromatography were 
same as the procedure used for NRS purification. The proteins 
purified by affinity chromatography were loaded onto a HiPrep 
desalting 26/10 column (GE Healthcare) and eluted with buffer E. 
The eluates were incubated with TEV protease at 4 ℃ overnight to 
cleave the MBP tag. The proteins were loaded onto a HiTrap 5-mL 
chelating HP column (GE Healthcare) pre-charged with Ni2+ and 
equilibrated with buffer E. The proteins in the flow-through 
fractions were loaded onto a HiLoad 16/600 Superdex 75 pg column 
(GE Healthcare) and eluted with appropriate buffers: buffer F (200 
mM NaCl, 10 mM Tris-HCl, pH 8.5) for crystallization; PBS for cell 
migration assays; buffer G (150 mM NaCl, 20 mM 
NaH2PO4/Na2HPO4, pH 6.5), and buffer H (150 mM NaCl, 20 mM 




Figure 13. Purification of UNE-N: the first Ni
2+
 affinity chromatography (A), the 
second Ni
2+
 affinity chromatography after TEV protease treatment (B), and size 
exclusion chromatography (C). Purity of the protein fractions was checked by 
SDS-PAGE analysis after each purification step.  
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The four CCR3 ED sequences are as follows: ED1 
(residues 1–40, MTTSLDTVET FGTTSYYDDV GLLCEKADTR 
ALMAQFVPPL), ED2 (residues 94–120, VRGHNWVFGH 
GMCKLLSGFY HTGLYSE), ED3 (residues 172–203, YETEELFEET 
LCSALYPEDT VYSWRHFHTL RM), and ED4 (residues 262–281, 
SSYQSILFGN DCERSKHLDL). MBP-fused CCR3 EDs were cloned 
into the pET-28a(+) plasmid between the Nde1 and Xho1 
restriction sites. Each construct contained a hexahistidine tag at the 
N-terminus. Recombinant proteins were overexpressed in Rosetta 
2(DE3), an E. coli strain. E. coli growth, protein expression, and 
purification steps up to hexahistidine tag affinity chromatography 
were same as those used for NRS purification. The proteins purified 
by affinity chromatography were loaded onto a HiLoad 16/600 
Superdex 200 pg column (GE Healthcare) and eluted with 





Figure 14. Purification of MBP fused CCR3 ED3: Ni
2+
 affinity chromatography (A) 
and size exclusion chromatography (B). Purity of the protein fractions was 
checked by SDS-PAGE analysis after each purification step. 
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2.2. Selenomethionine incorporation 
For the selenomethionine-derived protein, UNE-N was 
overexpressed in B834(DE3), an E. coli strain. The cells were 
cultured in media containing M9, minimal salts (Sigma-Aldrich), 
and amino acid mix containing L-selenomethionine. Protein 
expression and purification were conducted in the same manner as 
native UNE-N purification. 
 
2.3. Crystallography 
Purified UNE-N and CD proteins were crystallized at 22 ℃ using 
the sitting drop vapor diffusion method with 1 μL protein and 1 μL 
crystallization solution. Initial crystals of UNE-N (residues 4–77) 
were grown under a commercial crystallization screening condition 
with 0.01 M zinc sulfate, 0.1 M MES (pH 6.5), and 25% (v/v) 
polyethylene glycol (PEG) 550 monomethyl ether (Structure 
Screen 2, Molecular Dimensions). Initial crystals were further 
optimized for x-ray diffraction data collection. The crystal was 
cryoprotected with the reservoir solution supplemented with 12.5% 
of glycerol and flash-cooled in a nitrogen gas stream at 100 K. 
Single-wavelength anomalous diffraction data were collected at the 
5C beamline of Pohang Light Source, Republic of Korea, at an 
29 
anomalous peak wavelength (0.9796 Å). Collected data were 
processed at 1.9 Å resolution using the HKL2000 program suite32. 
The phase was solved by the single anomalous diffraction (SAD) 
method and an initial model was built using the AutoSol program of 
the PHENIX software package33 and improved by density 
modification using the automatic model building program Resolve34. 
For the final model, another diffraction data set was collected from 
a selenomethionine-derived protein crystal and processed at 1.65 
Å resolution. The model from the SAD method was used as a 





Figure 15. Crystals of UNE-N and their x-ray diffraction. (A) UNE-N crystals 
grown under the initial screening (left) and a further optimized condition (right). (B) 
A representative x-ray diffraction image from a UNE-N crystal. 
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Initial crystals of CD were grown under a commercial 
crystallization screening condition with 20% (v/v) glycerol, 0.04 M 
potassium phosphate, and 16% (w/v) PEG 8,000 (Wizard Classic 4, 
Rigaku, Tokyo, Japan). Initial crystals were further optimized for 
x-ray diffraction data collection. The crystal was flash-cooled in a 
nitrogen gas stream at 100 K. Diffraction data were collected at the  
AR-NW12A beamline of Photon Factory, Japan, and processed at 
2.25 Å resolution using the HKL2000 program suite32. The 
structure was solved by molecular replacement using the MOLREP 
program36 with the crystal structure of BmNRS (PDB ID: 2XGT)16 




Figure 16. Crystals of CD and their x-ray diffraction. (A) CD crystals grown under 
the initial screening (left) and a further optimized condition (right). (B) A 
representative x-ray diffraction image from a CD crystal. 
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Model building, refinement, and validation for all crystal 
structures were carried out with the WinCoot program37, 
phenix.refine38, and MOLPROBITY39, respectively. Statistics for 
data collection and refinement are summarized in Table 2. The 
secondary structure of our crystal structures were analyzed with 
the DSSP program40,41. 
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Table 2. Statistics on data collection and refinement. 
A. Data collection 
 UNE-N (SAD) UNE-N CD 
Beamline PLS-5C PLS-5C 
Photon Factory 
(AR-NW12A) 
Space group P6522 P65 P212121 







Unit cell angles () 90, 90, 120 90, 90, 120 90, 90, 90 
 Peak   
X-ray wavelength (Å ) 0.9796 0.9999 1.0000 








b 0.091 (0.401)a 0.102 (0.482)a 0.099 (0.467)a 
<I> / <σ(I)> 33.2 (12.5)a 15.2 (4.1)a 19.8 (4.5)a 
Completeness (%) 99.7 (100.0)a 93.7 (94.3)a 100.0 (100.0)a 
Redundancy 35.5 (38.1)a 7.1 (6.3)a 7.3 (7.1)a 
B. Model refinement  
PDB code  4ZYA 5XIX 
Resolution (Å )  30.00-1.65 30.00-2.25 
No. reflections  14,572 112,318 
Rwork / Rfree
c (%)  20.8 / 26.0 18.0 / 23.1 
No. of non-hydrogen atoms / average B-factor (Å 2) 
 Protein  1,184 / 24.26 13,690 / 34.68 
 Ligand/ion  9 / 28.10 162 / 38.74 
 Water  135 / 26.73 1,106 / 36.85 
R.m.s. deviations from ideal geometry 
 Bond lengths (Å )  0.010 0.008 
 Bond angles ()  1.130 1.101 
Ramachandrand 
Favored / Outliers (%)  98.6 / 0.0 97.0 / 0.4 
Poor rotamers (%)  0.8 0.8 
a 
Values in parentheses refer to the highest resolution shell. 
b Rmerge = hi  I(h)i – <I(h)>  / hi I(h)i, where I(h) is the intensity of 
reflection h, h is the sum over all reflections, and i is the sum over i 
measurements of reflection h. 
c Rwork =  | |Fobs| – |Fcalc| | /  |Fobs|, where Rfree is calculated for a randomly 
chosen 5% of reflections, which were not used for structure refinement and 
Rwork is calculated for the remaining reflections. 
d 
Values obtained using MolProbity.  
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2.4. NMR analysis 
Uniformly 15N- and 13C-labeled or 15N-labeled UNE-N were 
prepared by growing the cells in M9 medium, which contained 99% 
15NH4Cl and 99% [
13C]-D-glucose (Cambridge Isotope 
Laboratories, Tewksbury, MA, USA). The proteins for three-
dimensional (3D), hetero-nuclear nuclear Overhauser effect (NOE), 
and CLEANEX-PM NMR experiments were prepared at a 
concentration of approximately 0.6 mM in buffer G with 10% D2O. 
For NMR titration experiments with CCR3 EDs, 15N-labeled UNE-
N and unlabeled CCR3 EDs were prepared at concentrations of 
approximately 0.2–0.3 and 0.2–0.6 mM, respectively, in buffer F 
with 10% D2O. The NMR experiments were carried out at 298 K on 
a Bruker AVANCE 800 spectrometer (Billerica, MA, USA) equipped 
with a cryogenic probe and on a Jeol ECA 600 spectrometer 
(Tokyo, Japan). Backbone peak assignments of UNE-N were 
performed using a series of triple resonance spectra [3D HNCO, 
HN(CA)CO, HNCACB, CBCA(CO)NH]. NMR data were processed 
with the program NMRPipe42 and analyzed with the NMRViewJ 
program (http://www.onemoonscientific.com/ nmrviewj). The 
overall secondary structure was derived from chemical shifts using 
the TALOS+ program43. (Collaborated with Dr. Ki-Young Lee in 
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Research Institute of Pharmaceutical Sciences at Seoul National 
University) 
 
2.5. Cell culture 
A549, H460, WI-26, Daudi, Jurkat, and J774A.1 cells were grown 
in RPMI1640 medium (Hyclone) containing 10% fetal bovine serum 
and antibiotics (100 UI penicillin and 100 μg/mL streptomycin). 
DMEM medium containing the same supplements was used for RAW 
264.7 culture. Antibodies against NRS, tubulin, and CCR3 were 
purchased from Abcam (Cambridge, UK), Sigma-Aldrich, and 
Millipore (Billerica), respectively. (Collaborated with Dr. Min Chul 
Park, Dr. Peter C. Goughnour, and Dr. Seung Jae Jeong in Medicinal 
Bioconvergence Research Center at Seoul National University) 
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2.6. Cell migration assay 
Cell migration was determined by using a Transwell plate (5 μm 
pore size, 24-well, Corning). Cells were seeded in the upper 
chamber which had been pre-coated with 20 μg/mL fibronectin 
(BD Biosciences). NRS, UNE-N, and CD were separately added to 
the lower chamber as attractants and CCL5 as a positive control. 
After 4 h incubation, cells embedded in the fibronectin coated-
membrane were fixed and stained with hematoxylin (Sigma-
Aldrich). Non-migrated cells were removed with a cotton swab. 
The membrane was excised and mounted on slide glass. Migrated 
cells were monitored by microscopy using a 20X objective lens. 
(Collaborated with Dr. Min Chul Park, Dr. Peter C. Goughnour, and 
Dr. Seung Jae Jeong in Medicinal Bioconvergence Research Center 
at Seoul National University) 
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2.7. Secretion assay 
Cells were seeded and then cultured to 70% confluency. Cells were 
washed twice with PBS and then incubated under different 
conditions. Cultured media were harvested and then sequentially 
centrifuged at 1,000 ×g for 10 min and 10,000 ×g for 20 min to 
remove cells and debris, respectively. To precipitate proteins, 
trichloroacetic acid (TCA) (Sigma-Aldrich) was added to a 10% 
final concentration. After 12 h incubation, secreted proteins were 
pelleted by 20,000 ×g centrifugation. Precipitated proteins were 
resuspended in 100 mM HEPES (pH 8.0) and then separated by 
SDS-PAGE for immunoblotting. (Collaborated with Dr. Min Chul 
Park, Dr. Peter C. Goughnour, and Dr. Seung Jae Jeong in Medicinal 




Cells were lysed on ice by M-PER mammalian protein extraction 
reagent (Pierce Biotechnology). After removing cell debris by 
centrifugation, protein concentration was measured using Bradford 
solution (Bio-Rad). Proteins were separated by SDS-PAGE and 
then transferred to polyvinylidene fluoride membrane for 
immunoblotting with specific antibodies. (Collaborated with Dr. Min 
Chul Park, Dr. Peter C. Goughnour, and Dr. Seung Jae Jeong in 
Medicinal Bioconvergence Research Center at Seoul National 
University) 
 
2.9. Pull-down assay 
Four MBP-fused CCR3 EDs were incubated with NRS, UNE-N, CD, 
or CCL5 in PBS containing 5% glycerol, respectively. After 2 h 
incubation, amylose-resin (New England Biolabs) was added to pull 
down MBP-fused proteins. Precipitated proteins were resolved by 
SDS-PAGE. Co-precipitated proteins with MBP-fused CCR3 EDs 
were detected by Coomassie blue staining (Expedeon). 
(Collaborated with Dr. Min Chul Park, Dr. Peter C. Goughnour, and 
Dr. Seung Jae Jeong in Medicinal Bioconvergence Research Center 
at Seoul National University) 
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2.10. Statistical analysis 
Statistical analysis was performed using Dunnett's multiple 
comparison test and two-tailed Student's t-test. All graphs are 
presented as the mean ± standard deviation. Differences were 
considered statistically significant at a P value < 0.05. (Collaborated 
with Prof. Jae-Young Lee in College of Pharmacy at Chungnam 
National University) 
 
2.11. Data deposition 
The coordinates and structure factors of UNE-N and CD have been 
deposited in the Protein Data Bank (http://www.rcsb.org) under ID 




3.1. UNE-N shares a structural scaffold with the 
chemotactic N-terminal domain of BmNRS but 
exhibits unique features 
Human NRS is composed of a UNE-N, an ABD, an HR, and a 
catalytic domain. I determined the crystal structures of UNE-N 
(residues 4–77) and CD (residues 98–548) of NRS at 1.65 and 2.25 
Å resolution, respectively (Fig. 17). UNE-N is composed of two 
α-helices (α1, α2) and three β-strands (β1, β2, β3) with 
β1-α1-β2-β3-α2 topology. Three β-strands form a 
parallel/antiparallel mixed β-sheet (Fig. 18A). DALI server 
analysis for structural similarity searching with known protein 
structures predicted that the most similar structure to UNE-N is 
the UNE-N of B. malayi (PDB ID: 2KQR) with a Z-score of 7.3 and 
27% amino acid sequence identity44. Despite the low sequence 
identity, superposition of the UNE-N structures of human and B. 
malayi showed that the overall folds are very similar with a root-
mean-square deviation (RMSD) of 2.3 Å for all C atoms (Fig. 
18B). The overall structural similarity of UNE-Ns initially indicated 
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that the human UNE-N domain also plays a chemokine-like role 
like UNE-N of B. malayi. 
The lysine-rich helical motif, iSKsqLKnikK, was also 
observed at the N-terminus of helix α2, which implies interactions 





Figure 17. Domain composition of NRS. UNE-N, ABD, and HR indicate N-terminal 
extension domain, anticodon-binding domain, and hinge region, respectively. Three 
NRS constructs with full-length (residue 1–548), UNE-N (residue 4–77), and CD 





Figure 18. Crystal structure of UNE-N. (A) Crystal structure of UNE-N shown in 
rainbow cartoon representation depicting amino acid residues from N-terminus to 
C-terminus in blue to red. (B) Secondary-structure match superposition of UNE-
Ns of human and B. malayi (PDB ID: 2KQR). UNE-Ns of human and B. malayi are 
displayed in cartoon representation colored in blue and cyan, respectively. (C) 
Lysine-rich motifs of UNE-Ns of human and B. malayi are superposed with 
respect to the main chain of helix α2. Amino acid sequences of each lysine-rich 
motif are shown below. 
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Interestingly, the β2-loop3-β3 region exhibits 
remarkable structural differences. UNE-N has longer loop3 with 
Ser48–Arg54 residues and shorter β-strands in both ends of 
loop3 (β2 and β3), while UNE-N of B. malayi contains a β-
hairpin structure with a type Ⅱ β-turn (Lys45-Asp46-Gly47-
Lys48) and longer β-strands. NMR studies on UNE-N showed 
consistent results for the secondary structure propensity of loop3 
with the crystal structure (Table 3). 
In UNE-N of B. malayi, the β-hairpin structure that is 
equivalent to loop3 of human UNE-N was suggested as a minimal 
motif for the interaction with CXCR1/222. Loop3 of human UNE-N 
also seemed as the region for the receptor specificity to CCR3, and 
thus for subsequent CCR3-mediated signal transduction, which is 
further discussed below. 
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Table 3. NMR chemical shift-based prediction for the secondary structure of UNE-
N using the TALOS+ program. 
Residue Secondary structure Confidence level 
3 L L 0.76 
4 A L 0.76 
5 E L (E) 0.19 
6 L E 0.69 
7 Y E 0.81 
8 V E 0.56 
9 S L 0.19 
10 D L 0.52 
11 R L 0.31 
12 E L 0.65 
13 G L 0.93 
14 S L 0.84 
15 D L 0.66 
16 A L 0.8 
17 T L 0.92 
18 G L 0.97 
19 D L 0.96 
20 G L 0.96 
21 T L 0.87 
22 K L 0.57 
23 E L 0.51 
24 K L 0.79 
25 P L 0.9 
26 F L 0.87 
27 K L 0.85 
28 T L 0.81 
29 G L (H) 0.84 
30 L H 0.62 
31 K H 0.91 
32 A H 0.9 
33 L H 0.87 
34 M H 0.83 
35 T H 0.74 
36 V H (L) 0.35 
37 G L 0.5 
38 K L 0.91 
39 E L 0.94 
40 P L 0.86 
41 F L 0.93 
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42 P L 0.93 
43 T L (E) 0.81 
44 I E 0.26 
45 Y E 0.65 
46 V L (E) 0.28 
47 D L (E) 0.85 
48 S L 0.8 
49 Q L 0.89 
50 K L 0.89 
51 E L 0.88 
52 N L 0.87 
53 E L 0.89 
54 R L 0.79 
55 W E 0.17 
56 N E 0.59 
57 V E 0.2 
58 I L 0.43 
59 S L (H) 0.72 
60 K H 0.66 
61 S H 0.94 
62 Q H 0.96 
63 L H 0.97 
64 K H 0.96 
65 N H 0.96 
66 I H 0.98 
67 K H 0.98 
68 K H 0.97 
69 M H 0.95 
70 W H 0.93 
71 H H 0.87 
72 R H 0.63 
73 E H 0.32 
74 Q L (H) 0.14 
75 M L (H) 0.53 
76 K L 0.57 
 
Note: H, E, and L in the secondary structure column represent α-helix, β-
strand, and loop, respectively. The secondary-structure elements in parenthesis 
are derived from the crystal structure of UNE-N. 
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In addition, the loop3 region was the most dynamic part in 
UNE-N from the 1H-15N hetero-nuclear NOE experiment (Fig. 19) 
and the amide proton exchange rates for the loop3 region and the 
N-terminus of helix α2 were higher than those for the other parts 
(Fig. 20 and Fig. 21), which further supports the dynamic nature of 








N NOE data of UNE-N. Hetero-nuclear NOE 
values are plotted against UNE-N residues. Residues showing the lowest and 
second-lowest NOE values are indicated by red and blue down arrows, 
respectively (red arrows: hetero-nuclear NOE value < 0.8, blue arrows: 0.8 < 
hetero-nuclear NOE value < 0.85). N-terminal and C-terminal residues are 
excluded for potential fast motions. The spectra were recorded at 298 K in a 
buffer containing 150 mM NaCl, 20 mM NaH2PO4/Na2HPO4 (pH 6.5), and 10% D2O. 
The residues showing unclear peaks because of overlaps or inadequate signal to 




Figure 20. Dynamics of UNE-N obtained from CLEANEX-PM spectra. (A–D) 
Relative peak intensities measured from CLEANEX-PM spectra of UNE-N are 
plotted against residues number. The data were acquired at various proton-
exchange mixing times of 20 (A), 50 (B), 100 (C), and 200 ms (D), respectively. 




N HSQC and representative CLEANEX-PM 
spectrum (200 ms) of UNE-N. The two spectra are colored in black and blue, 
respectively. All spectra were recorded at 298 K in a buffer containing 150 mM 
NaCl, 20 mM NaH2PO4/Na2HPO4 (pH 6.5), and 10% D2O.  
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Figure 21. CLEANEX-PM spectrum represented on crystal structure of UNE-N. (A) 
Plot of peak intensities on the CLEANEX-PM spectrum of UNE-N against residue 
number. Residues with relative values of proton exchange higher than 1, between 
0.1 and 1, and lower than 0.1 are colored in magenta, blue, and green, respectively. 
The spectrum was obtained with a proton-exchange mixing time of 20 ms and 
recorded at 298 K in a buffer containing 150 mM NaCl, 20 mM NaH2PO4/Na2HPO4 
(pH 6.5), and 10% D2O. (B) A stereo-view image of UNE-N on which residues 
are mapped and colored as in (A). 
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When I compared 1H-15N HSQC spectrum of UNE-N 
including further C-terminal residues (UNE-N111, residues 1–111) 
with the spectrum of UNE-N (Fig. 22), most peaks for residual 
residues 78–111 of UNE-N111 clustered around 8.2 ppm, indicating 
that the residual region adopts an unfolded state and does not affect 
















N HSQC spectrum of 
UNE-N111 (residues 1–111). (C) Overlay of the spectra of UNE-N (black) and 
UNE-N111 (magenta). Most peaks for residual residues 78–111 of UNE-N111 
clustered around 8.2 ppm. All spectra were recorded at 298 K in a buffer 
containing 150 mM NaCl, 20 mM NaH2PO4/Na2HPO4 (pH 6.5), and 10% D2O. 
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I also determined the crystal structure of CD of NRS 
using the molecular replacement method with the crystal structure 
of BmNRS (Fig. 23). CD shares considerable structural similarities 
with NRSs from B. malayi, Pyrococcus horikoshii, and Entamoeba 
histolytica, as calculated by the DALI server44. The catalytic domain 
of CD features a nucleotide-binding site with an antiparallel β-
sheet flanked with α-helices, which is a structural characteristic 
of the class 2 ARS family. The dimeric interface of CD is widely 
spread through ABD and the catalytic domain of 3,800 Å2, which 
covers approximately 18% of the monomeric surface area of CD, as 





Figure 23. Crystal structure of CD. ABD, HR, and catalytic domain are colored in 
green, blue, and purple, respectively. The homodimeric pair is colored in gray. 
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3.2. Th1 and Th2 cytokines induce NRS secretion 
from macrophages 
Autoantibodies against NRS have been detected in the sera of ILD 
patients and most cytokine-like ARSs are secreted from immune 
cells46,47. Therefore, NRS secretion levels in seven different cell 
lines were measured. Seven cell lines (A549, H460, WI-26, Daudi, 
Jurkat, RAW 264.7, and J774A.1) were incubated in serum-free 
medium for 12 h and proteins secreted into the medium were 
precipitated by TCA. The precipitated proteins were separated and 
the presence of NRS was determined by western blot analysis with 
an NRS-specific antibody. Among the seven tested cell lines, NRS 
was detected in the culture media obtained from macrophage cell 
lines, RAW 264.7 and J774A.1 (Fig. 24). Under the same conditions, 
release of tubulin into the medium was not observed, confirming 
that NRS in the culture medium was not caused by cell lysis. These 




Figure 24. Secretion of NRS from macrophages. Seven cell lines were tested for 
NRS secretion. A549, adenocarcinomic human alveolar basal epithelial cell line; 
H460, human lung cancer cell line (NCI-H460); WI-26, human diploid lung 
fibroblast cell line; Daudi, human B lymphoblast cell line; Jurkat, human T 
lymphocyte cell line; RAW 264.7, mouse macrophage cell line; J774A.1, mouse 
monocyte/macrophage cell line. Secreted NRS was determined by western blotting 
after 12 h culture in serum-free media. 
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To further determine whether NRS secretion is 
influenced by other stimuli, RAW 264.7 and J774A.1 cells were 
treated with three representative cytokines, tumor necrosis factor 
(TNF)-α, interferon (IFN)-γ, and transforming growth factor 
(TGF)-β. TNF-α and IFN-γ influence Th1 differentiation and 
TGF-β regulates Th2 differentiation. All three cytokines 
increased NRS secretion from the macrophage cells (Fig. 25), 
indicating that increased NRS secretion by cytokines plays an active 
role in Th1 and Th2 responses, resulting in immune cell recruitment. 
59 
 
Figure 25. Induction of NRS secretion by cytokines. RAW 264.7 (A) and J774A.1 
(B) cells were incubated with three cytokines, TNF-α (10 ng/mL), IFN-γ (150 
U/mL), and TGF-β (20 ng/mL) for 4 h. Secreted proteins were precipitated by 
TCA solution and detected by immunoblotting.  
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3.3. UNE-N exclusively elicits chemotactic activities 
of NRS on Daudi and Jurkat cells 
To narrow down the functional determinants of NRS for the 
chemokine activities on lymphocytes, iDCs, and CCR3-transfected 
HEK293 cells18,19 and to examine whether the evolutionarily 
acquired UNE-N plays a role in the chemokine activity of NRS, cell 
migration assays were conducted with three different constructs, 
NRS, UNE-N (residues 1–77), and CD (residues 98–548). Daudi, 
Jurkat, and H460 cell lines were used as representative B cells, T 
cells, and cancer cells, respectively, and seeded into the upper 
chamber coated with fibronectin. Then, the lower chamber media 
were treated with NRS, UNE-N, and CD at 0.1, 1, and 10 nM. 
Microscopic analysis showed that NRS and UNE-N induced the 
migration of Daudi and Jurkat cells, while CD did not affect the 
migration of any cells. No migration effect was observed for H460 
cells, further supporting that the chemokine activity of NRS 




Figure 26. Chemokine activity of UNE-N. (A) Cell migration induced by NRS. Daudi, 
Jurkat, and H460 cells were seeded in the fibronectin-coated upper chamber of a 
Transwell and NRS, UNE-N, and CD were added to the lower chamber at 1 nM. 
After 4 h incubation, fibronectin-coated membranes were harvested. Migrated 
cells embedded in the harvested membrane were stained and then monitored by 
microscopy. (B,C) Cell migrations induced by various concentrations of NRS. 
Migration of Daudi (B) and Jurkat (C) cells was quantified by cell counting. Labels 
on the X-axis represent NRS construct and concentration: F, full-length NRS; N, 
UNE-N; C, CD. Error bars indicate the mean ± standard deviation from the 
average of three independent experiments. Significant differences were determined 
by Dunnett's multiple comparison test. *P < 0.05.  
62 
When NRS was added to both the upper chamber and the 
lower chamber, the migration of Jurkat cells was blocked, which 
shows that NRS induced chemotaxis rather than chemokinesis (Fig. 
27). Collectively, the data reveal that the evolutionally acquired 
UNE-N is the functional motif necessary and sufficient for inducing 




Figure 27. NRS induces chemotaxis, not chemokinesis. The migration of Jurkat cells 
was blocked when 1 nM of NRS was added to both the upper chamber and the 
lower chamber of a Transwell. Error bars indicate the mean ± standard deviation 
from the average of three independent experiments. Significant differences were 
determined by Dunnett's multiple comparison test. *P < 0.05. 
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3.4. UNE-N directly interacts with CCR3 extracellular 
domains 
To further elucidate whether UNE-N exerts its chemokine activity 
via CCR3, the migration of Daudi and Jurkat cells by UNE-N was 
tested when CCR3 expression was suppressed by a specific CCR3-
targeting siRNA (si-CCR3) (Fig. 28A–C). The chemokine activities 
of NRS and UNE-N were significantly reduced as CCL5, a well-
established chemokine of CCR330, which was used as a positive 
control (Fig. 28D,E). These results indicate that UNE-N elicits its 




Figure 28. CCR3 mediates chemokine activity of NRS. (A) CCR3 expression in 
H460, Daudi, and Jurkat cells was determined by immunoblotting. (B,C) 
Confirmation of CCR3 knock-down by si-CCR3. CCR3 expression in Daudi (B) 
and Jurkat (C) cells after si-CCR3 treatment was determined by immunoblotting. 
(D,E) Effects of CCR3 knock-down on NRS-induced cell migration of Daudi (D) 
and Jurkat (E) cells. The cells down-regulated by CCR3-targeting siRNA (si-
CCR3) were used for the migration assay. Error bars indicate the mean ± 
standard deviation from the average of three independent experiments. Significant 
differences were determined by Student's t-test. *P < 0.05.  
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Next, to narrow down the binding propensities of UNE-N 
with respect to CCR3 EDs, the in vitro interaction between NRS and 
CCR3 EDs was evaluated. CCR3 ED1, ED2, ED3, and ED4 with a 
MBP tag at each N-terminus were purified and incubated with NRS, 
UNE-N, CD, or CCL5. MBP control without CCR3 EDs did not pull 
down NRS, UNE-N, CD, and CCL5. Interestingly, NRS and UNE-N 
were co-precipitated with CCR3 EDs, while CD and CCL5 were not 
pulled down (Fig. 29). Particularly, CCR3 ED3 bound more strongly 
to NRS/UNE-N than CCR3 ED1 and ED2 did and a weak interaction 
between CCR3 ED4 and NRS/UNE-N was observed. CCL5 was not 
co-precipitated with CCR3 EDs, which needs further attention 
regarding to the condition of in vitro interaction between CCL5 and 
CCR3 EDs as will be discussed below. These results indicate that 
UNE-N exerts CCR3-mediated chemokine activity and directly 





Figure 29. Direct interaction of UNE-N with CCR3. (A–D) Interaction between NRS 
and CCR3 EDs. For in vitro binding assay, MBP without CCR3 EDs (as a control, 
lane ‘-’) and four MBP-fused CCR3 EDs (ED1–ED4, lanes 1–4) were 
separately incubated with NRS (A), UNE-N (B), CD (C), and CCL5 (D), and then 
precipitated by maltose resin. Co-precipitated proteins were resolved by SDS-
PAGE and detected by Coomassie blue staining. 
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3.5. Loop3 of UNE-N is an effector motif for CCR3 
interactions 
To further investigate the binding mode of UNE-N to CCR3, 1H-
15N HSQC spectra of UNE-N were measured in the absence and 
presence of four individual CCR3 EDs. It showed that CCR3 ED3 
caused the most perturbed spectra peaks with predominant 
resonance broadenings rather than chemical shift perturbations. 
Overall resonance broadenings can be explained by the remarkable 
increases in transverse relaxation rates (R2) of UNE-N when it 
bound to MBP-fused CCR3 EDs. Similar peak changes were 
observed in the spectra of UNE-N titrated with CCR3 ED1 to a 
lesser extent. CCR3 ED2 caused slight resonance broadenings 
without chemical shift changes and CCR3 ED4 did not cause 
noticeable spectral changes. These results indicate that the binding 
preference for UNE-N is CCR3 ED3, ED1, ED2, and ED4, in a 
descending order, which is consistent with the pull-down assay 
results in that UNE-N binds most strongly to CCR3 ED3. 
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The degrees of resonance broadenings may be derived 
from the ratios of peak intensities of the spectra in the absence and 
presence of CCR3 EDs. When these values elicited by CCR3 ED3, 
ED1, and ED2 were plotted with respect to UNE-N residues, the 
average ratio/standard deviation for each plot was 0.530/0.066 
(ED3), 0.575/0.052 (ED1), and 0.794/0.056 (ED2), respectively 
(Fig. 30). Larger standard deviation values for UNE-N residues 
can be interpreted as UNE-N residues are more specifically 
affected by CCR3 binding and residue-by-residue analysis of 
UNE-N would reveal the binding mode more in detail. 
To identify the interacting residues of UNE-N with each 
CCR3 ED, the resonance broadenings and chemical shift 
perturbations were quantified. In the presence of CCR3 ED3, Glu51 
and Asn52 in loop3 and Lys60 in helix α2 showed the largest 




Figure 30. Key residues of UNE-N involved in the interaction with CCR3. (A–C) 
Ratios of peak intensities are plotted against UNE-N residues in the presence of 
CCR3 ED3 (A), ED1 (B), and ED2 (C), each of which is fused to MBP. The molar 
ratio of UNE-N to MBP-fused CCR3 EDs used was approximately 1:1. Residues 
showing large resonance broadenings (ratio < 0.85) and chemical shift 
perturbations are marked with red and blue down arrows, respectively. All titration 
experiments were carried out at 298 K in a buffer containing 150 mM NaCl, 20 mM 
NaH2PO4/Na2HPO4 (pH 7.5), and 10% D2O. Residues showing unclear peaks 
because of overlaps or inadequate signal to noise (S/N) were omitted and are 
denoted by * marks. 
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Considering that the conformational change on the 
intermediate NMR time scale increases resonance broadening of 
corresponding peaks, loop3 (Glu51 and Asn52) and the N-terminus 
of helix α2 (Lys60) undergo the most remarkable conformational 
changes when UNE-N interacts with CCR3 ED3. Slight chemical 
shift perturbations upon binding to CCR3 ED3 were observed for 
Ala4, Tyr7, Ala16, Lys50, Ile58, Gln62, Ile66, His71, Gln74, Met75, 
Lys76, and Ser77 (Fig. 31), suggesting slight structural changes on 




Figure 31. Chemical shift perturbations of UNE-N upon binding to CCR3 ED3. 
Expanded views of 12 residue peaks with relatively large chemical shift changes 
are shown on the right-hand side. The molar ratios of UNE-N/MBP-fused CCR3 
ED3 were approximately 1:0, 1:1, and 1:2, which are color-mapped onto peaks in 




N HSQC spectra were recorded at 
298 K in a buffer containing 150 mM NaCl, 20 mM NaH2PO4/Na2HPO4 (pH 7.5), 
and 10% D2O. 
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Following titration with CCR3 ED1, Gln49 in loop3 
showed the largest resonance broadening, while Glu51, Asn52, and 
Lys60 showed the second largest broadening (Fig. 30B), supporting 
that loop3 of UNE-N is mainly involved in binding to CCR3 ED1. 
Chemical shift perturbations upon binding to CCR3 ED1 were 
observed for Ala4, Ala16, Lys50, Ile58, Met75, Lys76, and Ser77, 
with lower values than those caused by CCR3 ED3 (Fig. 32). 
Similar to the titration with CCR3 ED1, Gln49 in loop3 elicited the 
largest resonance broadening and Glu51, Asn52, Arg54, and Lys60 
caused the second largest in the presence of CCR3 ED2 (Fig. 30C). 
Collectively, these results suggest that loop3 in UNE-N plays a 
major role in binding to CCR3 and is an effector motif for the 




Figure 32. Chemical shift perturbations of UNE-N upon binding to CCR3 ED1. 
Expanded views of seven residue peaks with relatively large chemical shift 
changes are shown on the right-hand side. The molar ratios of UNE-N/MBP-
fused CCR3 ED1 were approximately 1:0, 1:1, and 1:2, which are color-mapped 




N HSQC spectra were 
recorded at 298 K in a buffer containing 150 mM NaCl, 20 mM NaH2PO4/Na2HPO4 
(pH 7.5), and 10% D2O. 
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3.6. Loop3 region of UNE-N is structurally distinct 
from UNE-N of BmNRS targeting different receptors 
To gain insights into the structural contribution of loop3 of UNE-N 
in target receptor selection, nine UNE-N sequences from 
representative eukaryotes were aligned; human, monkey, mouse, 
bird, frog, fish, insect, and two nematodes (Fig. 33). Two aromatic 
amino acid residues near loop3, Tyr7 and Trp55, are highly 
conserved among various NRSs. Comparison of the structures of 
UNE-Ns from human and B. malayi revealed that the secondary 
structure composition of loop3 region was notably different, 
although the overall structures were similar and some characteristic 




Figure 33. Sequence alignment of UNE-Ns from nine eukaryotic NRSs: H.sap, 
Homo sapiens; M.fas, Macaca fascicularis; M.mus, Mus musculus; G.gal, Gallus 
gallus; X.lae, Xenopus laevis; C.mil, Callorhinchus milii; D.mel, Drosophila 
melanogaster; C.ele, Caenorhabditis elegans; B.mal, Brugia malayi. Residues 
identical or conserved in UNE-Ns are colored in blue or cyan, respectively. 
Secondary structure elements of NRS and BmNRS are represented above and 
below the sequences with red tube for α-helix and blue arrow for β-strand, 
respectively. Representative residues of conformational importance are denoted 
with red down arrows. The red dashed box and asterisks denote the conserved 
tRNA-binding motif.  
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The aromatic side chains of Tyr7 and Trp55 of NRS 
interact with each other via a pi-pi interaction, stabilizing protein 
folding. On the opposite side of the Typ7-Trp55 interface, the side 
chain of Arg54, which is conserved in vertebrates, also stabilized 
Trp55 via a cation-pi interaction according to the CaPTURE web 
server calculations48. Additionally, the negatively charged carboxyl 
group of Asp47, which is conserved in vertebrates, stabilized the 
positively charged guanidinium group of Arg54 electrostatically. For 
UNE-N of BmNRS, Tyr4 and Trp51 correspond to Tyr7 and Trp55 
of human NRS, respectively, and form a pi-pi interaction through 
aromatic side chains of Tyr-Trp. However, BmNRS lacks the basic 
residue corresponding to Arg54 of human NRS, but the positively 
charged guanidinium group of Arg42 (equivalent to Asp47 of human 
NRS) alternatively occupies the Arg54 site of human NRS and 
interacts with Trp51 via a cation-pi interaction (Fig. 34). The 
stable conformation of Arg54 of human NRS induces forced bending 
of the peptide backbone of Glu53-Arg54-Trp55 and the region 
forms a loop, while BmNRS adopts an antiparallel β-sheet 
structure in the region. Together with the NMR titration results, the 
different conformation of the loop3 region may explain the target 
receptor specificity of UNE-Ns. 
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Figure 34. Residues on β2-loop3-β3 regions of UNE-Ns of human and B. malayi. 
Cα atoms of Trp55-Ser59 of human NRS and Trp51-Ser55 of BmNRS are 
superposed. Human NRS and BmNRS are colored in blue and cyan, respectively 





Evolutionary pressure to obtain novel functions in eukaryotic cell 
systems has resulted in the incorporation of non-translational 
additional domains into ARSs and has maintained ARS splicing 
variants with catalytic nulls8,49. In human NRS, domain addition at 
the N-terminus has been observed, but specific functional roles 
elicited by UNE-N remain unclear. Our crystal structure of UNE-N 
of NRS provides functional insight, as the overall structure was 
similar to the chemotactic UNE-N domain of BmNRS which 
interacts with two chemokine receptors, CXCR1 and CXCR2. 
The UNE-N domains of human NRS and BmNRS are 
structurally similar and both exhibit non-translational chemokine 
activities that induce the migration of immune cells. Interestingly, 
structurally similar UNE-Ns from human NRS and BmNRS target 
different chemokine receptors, CCR3 and CXCR1/2, respectively, 
and it is very important to elucidate how these structurally similar 
domains can recognize their matching receptors. To investigate how 
this novel domain fold interacts with chemokine receptors and why 
each UNE-N targets different receptors, I elucidated the 
interaction mode between UNE-N of NRS and CCR3 EDs by 
conducting pull-down assays and NMR perturbation experiments. 
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The results may not demonstrate a physical interaction between 
UNE-N and ‘native’ CCR3 but clearly show that UNE-N 
interacts with EDs derived from CCR3. If UNE-N did not interact 
with CCR3 at all, UNE-N would not be pulled down together with 
CCR3 EDs in the in vitro pull-down assay50. CCL5, a CCR3-
targeting chemokine, was not pulled down together with MBP-fused 
CCR3 EDs. When chemokines binds to chemokine receptors, post-
translational modifications such as tyrosine sulfation could be a key 
factor51. Thus, the interaction between CCL5 and MBP-fused CCR3 
EDs in the pull-down assays might not be observed since MBP-
fused CCR3 EDs were purified from E. coli and would not contain 
necessary post-translational modifications for the interaction. 
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In addition to the in vitro pull-down assays, NMR 
perturbation experiments were implemented with UNE-N and 
CCR3 EDs which further support the direct interaction between 
UNE-N and CCR3 EDs. NMR perturbation experiment was also 
used for the validation of interactions between CCR3 and CCL11 
(eotaxin-1), a well-known CCR3 chemokine, in which a 
synthesized ED1 peptide derived from CCR3 was used52. Similarly, 
the interaction between CCL5 and CCR5 was investigated using 
peptides derived from CCR5 EDs53. Taken all together, the data 
from pull-down assays and NMR perturbation experiments would 
provide reliable evidences for the direct interaction between UNE-
N and CCR3. 
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NMR perturbation experiment is a powerful tool as well 
for probing the interfaces of a protein with its binding partner54-56. 
According to the perturbation experiments for 15N-labeled UNE-N 
with MBP-fused CCR3 EDs, peaks showing more sensitive 
broadening than other peaks were detected, which is often observed 
following titration with a protein ligand. However, the degree of 
chemical shift was not sufficient to assign specific residues affected 
by the titration experiments (Fig. 31 and Fig. 32). The degrees of 
peak broadening of UNE-N residues were affected by additions of 
CCR3 ED3, ED1, and ED2 in a descending order of reducing 
sensitivity while maintaining similar broadening patterns plotted by 
UNE-N residues. Residues in the loop3 region of UNE-N were 
mainly influenced by titrations with CCR3 EDs. For UNE-N of 
BmNRS, the β2-loop3-β3-α2 motif has been suggested to 
interact with CXCR1/2 based on structural comparison with other 
chemokines22. The β2-loop3-β3 regions of UNE-N in NRS and 
BmNRS are quite different in amino acid sequence and structure as 
described above. Thus, different conformations in the determinant 
β2-loop3-β3 region of UNE-Ns may mainly contribute to the 
selection of their target receptors. 
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Additionally, I found that Trp70 in human NRS, equivalent 
to Tyr66 in BmNRS, is a highly conserved aromatic residue in helix 
α2 and forms a pi-pi interaction with Phe41 in the adjacent loop2, 
while Tyr66 in BmNRS forms a pi-pi interaction with Trp63 in the 
same α2 helix (Fig. 35). This subtle structural difference may 
leave loop2 of BmNRS more flexible16 than that of human NRS, 





Figure 35. Residues on the loop2 and α2 regions of UNE-Ns of human and B. 
malayi. Cα atoms of Trp55–Ser59 of human NRS and Trp51–Ser55 of BmNRS are 
superposed. Human NRS and BmNRS are colored in blue and cyan, respectively. 
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H hetero-nuclear NOE values of UNE-N of 
BmNRS plotted against residue number. Loop2 and loop3 regions of UNE-N of 
BmNRS show peaks in the backbone RMSD curve. (Reprinted from Crepin, T. et al. 
A hybrid structural model of the complete Brugia malayi cytoplasmic asparaginyl-
tRNA synthetase. Journal of molecular biology 405, 1056-1069, 
doi:10.1016/j.jmb.2010.11.049 (2011), with permission from Elsevier) 
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The immunogenicity of antigenic materials interacting 
with receptors on antigen-presenting cells is highly augmented and 
the balance among immunomodulatory cytokines is a key factor in 
the life and death of cells 57,58. As shown in the cell migration 
assays with UNE-N and other constructs of NRS, UNE-N 
exhibited chemokine activities in CCR3-expressing cells. 
Considering that autoantibodies against NRS have been detected in 
the sera of patients with autoimmune diseases such as ILD and 
myositis46,59-62, the chemokine activity of NRS could be closely 
related to proinflammatory signaling. ILD is a well-known major 
clinical feature of patients with anti-KS and secreted NRS may 
elicit CCR3-mediated proinflammatory signaling in ILD 
development. And modulators of the NRS-CCR3 signaling axis may 
provide a niche for elucidating the mechanism of ILD and alleviating 
CCR3-mediated malignances. 
Cytosolic NRS secretion from macrophages and specific 
targeting of CCR3 on immune cells may be explained as a “danger 
signal” from cells confronting stressful environments18,63. However, 
the exact roles of autoantibodies against secreted NRS and 
pathophysiological connections between NRS-CCR3 signaling and 
immune diseases require further investigations. Structural 
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information of UNE-N and CD of NRS at an atomic level and the 
interaction mode between UNE-N and CCR3 may provide a 
foundation for evaluating NRS-CCR3 signaling and its correlation 
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6. 국문 초록 
Antisynthetase syndrome 은 autoimmune disease 의 하나로, 
aminoacyl-tRNA synthetase 에 대한 antibody 가 만들어진다. 그 중에서 
asparaginyl-tRNA synthetase 에 대한 autoantibody 인 anti-KS 의 발생은 
interstitial lung disease 와 밀접한 관련이 있는 것으로 보이는데 아직 생성 
기전이 명확하게 밝혀지지 않았다. 
본 연구에서는 human asparaginyl-tRNA synthetase 의 N 말단 
부위의 결정구조를 규명하였고 그 구조가 Brugia malayi asparaginyl-tRNA 
synthetase 의 N 말단 부위와 유사하다는 것을 밝혔다. 또한 human 
asparaginyl-tRNA synthetase 의 N 말단 부위가 CC chemokine receptor 
3 와 직접 결합하여 독립적으로 chemokine 활성을 가진다는 것을 보였고, 그 
결합 방식을 NMR spectroscopy 기법을 이용하여 설명하였다. 
나아가, interstitial lung disease 의 발달과 autoantibody 의 생성에 
있어 human asparaginyl-tRNA synthetase 의 증가된 분비에 따른 
비정상적인 N 말단 부위의 chemokine 활성이 잠재적 역할을 할 것이라 
제시하였다. 
 
주요 단어: Human asparaginyl-tRNA synthetase (NRS), chemokine, CC 
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